scholarly journals pH-operated hybrid silica nanoparticles with multiple H-bond stoppers for colon cancer therapy

RSC Advances ◽  
2015 ◽  
Vol 5 (80) ◽  
pp. 64932-64936 ◽  
Author(s):  
C. Théron ◽  
A. Gallud ◽  
S. Giret ◽  
M. Maynadier ◽  
D. Grégoire ◽  
...  

Controlled delivery of a chemotherapeutic drug from pH-sensitive hybrid silica nanocarriers efficiently targets colon carcinoma cells. The drug, blocked by cyanuric acid as stopper, is autonomously released inside the cancer cells.

2008 ◽  
Vol 389 (6) ◽  
Author(s):  
Rebecca S. Henkhaus ◽  
Eugene W. Gerner ◽  
Natalia A. Ignatenko

Abstract Kallikrein 6 (KLK6) is a trypsin-like serine peptidase whose relevance in various types of cancers is currently being explored. Previous studies have shown that KLK6 mRNA is upregulated in colon and gastric cancers; however, the regulatory mechanisms and phenotypic consequences of this upregulation are largely unknown. Activating K-RAS mutations are common in colon cancer, occurring in approximately 50% of cases. We have recently reported the upregulation of KLK6 mRNA in Caco2 human colon cancer cells stably transfected with a mutant K-RAS allele (K-RASG12V). In this study we examined the pattern of K-RAS-dependent KLK6 expression and secretion in colon cancer cells. Using pharmacological inhibitors of pathways downstream of K-RAS, we could show that the PI3K and p42/44 MAPK pathways play an important role in the induction of KLK6 in mutant K-RAS-expressing colon cancer cells. Increased KLK6 expression enhanced colon cancer cell migration through laminin and Matrigel. Inhibition of KLK6 using small interference RNA treatment or a specific KLK6 antibody in Caco2 cells stably expressing the mutant K-RAS and in SW480 cells carrying a mutation in the K-RAS oncogene resulted in a reduction in invasiveness through cell culture inserts. These data support the oncogenic role of KLK6 in colorectal cancer.


2018 ◽  
Vol 18 (3) ◽  
pp. 428-437 ◽  
Author(s):  
Mahendra Pal Singh ◽  
Ki Hun Park ◽  
Tejinder Pal Khaket ◽  
Sun Chul Kang

Background: Colon cancer is the second most common cancer to cause death worldwide. About half of colon cancers patients require adjuvant therapy to control relapse following surgical resection. Therefore, abolition of tumor cell progression using an effective chemotherapeutic agent holds a feasible approach to treat patients suffering from colon cancer. In the present study, we evaluated the effects of geranylated flavonoid CJK-7, isolated from Paulownia tomentosa on HCT-116 human colon carcinoma cells. Materials and Methods: The effects of CJK-7 as an active component on HCT-116 cells programmed cell death and its underlying molecular mechanism were examined by using MTT assay, morphological assessment, H2DCFDA staining, Fura-2AM staining, Hoechst-33342 staining, comet assay, Acridine orange staining, mitochondrial membrane potential (ΔΨm) assay and Western blot analyses. Results and Conclusion: The results revealed that, CJK-7 was capable of inducing caspase-dependent cell death events in cancer cells. Moreover, it was involved in up-regulation of autophagy signaling as evidenced by enhanced expression of LC3I/II. We also noticed stimulated expression of endoplasmic reticulum stress markers and phosphorylation of c-Jun NH2-terminal kinase (JNK), which was associated with up-regulated expression of p53, PUMA, Atg5 and Beclin-1, and down-regulation of Bcl-2, stressing the interaction of ROS on the aforementioned signaling. Furthermore, exposure to ROS scavengers (N-acetyl-l-cysteine (NAC), and JNK-specific inhibitor SP600125) significantly reversed the effects of CJK-7 by down-regulating apoptosis and autophagy signatures in HCT-116 cancer cells. Collectively our findings clarify the ROS-dependent regulatory effect of CJK-7 on programmed cell death signaling events in HCT-116 cancer cells while depicting its virile pro-oxidant capacity.


Langmuir ◽  
2015 ◽  
Vol 31 (12) ◽  
pp. 3753-3762 ◽  
Author(s):  
Cristina Giménez ◽  
Cristina de la Torre ◽  
Mónica Gorbe ◽  
Elena Aznar ◽  
Félix Sancenón ◽  
...  

RSC Advances ◽  
2019 ◽  
Vol 9 (14) ◽  
pp. 8025-8038 ◽  
Author(s):  
Sayoni Nag ◽  
Krishnendu Manna ◽  
Krishna Das Saha

Tannic acid and AuNP-TA lead to death of colon cancer cells via the ROS/p53/Akt pathway, and AuNP-TA is more potent.


RSC Advances ◽  
2015 ◽  
Vol 5 (37) ◽  
pp. 29008-29016 ◽  
Author(s):  
Kislay Roy ◽  
Rupinder K. Kanwar ◽  
Chun Hei Antonio Cheung ◽  
Cassandra Lee Fleming ◽  
Rakesh N. Veedu ◽  
...  

EpCAM and nucleolin translocate into the cytoplasm and nucleus that facilitates enhanced uptake of nanocarrier to specifically target cancer cells.


Talanta ◽  
2019 ◽  
Vol 202 ◽  
pp. 251-258
Author(s):  
A. Procopio ◽  
C. Cappadone ◽  
N. Zaccheroni ◽  
E. Malucelli ◽  
L. Merolle ◽  
...  

2012 ◽  
Vol 2012 ◽  
pp. 1-8 ◽  
Author(s):  
Claudia Schlimper ◽  
Andreas A. Hombach ◽  
Hinrich Abken ◽  
Ingo G. H. Schmidt-Wolf

Adoptive therapy of malignant diseases with cytokine-induced killer (CIK) cells showed promise in a number of trials; the activation of CIK cells from cancer patients towards their autologous cancer cells still needs to be improved. Here, we generated CIK cellsex vivofrom blood lymphocytes of colorectal cancer patients and engineered those cells with a chimeric antigen receptor (CAR) with an antibody-defined specificity for carcinoembryonic antigen (CEA). CIK cells thereby gained a new specificity as defined by the CAR and showed increase in activation towards CEA+colon carcinoma cells, but less in presence of CEA−cells, indicated by increased secretion of proinflammatory cytokines. Redirected CIK activation was superior by CAR-mediated CD28-CD3ζ than CD3ζ signaling only. CAR-engineered CIK cells from colon carcinoma patients showed improved activation against their autologous, primary carcinoma cells from biopsies resulting in more efficient tumour cell lysis. We assume that adoptive therapy with CAR-modified CIK cells shows improved selectivity in targeting autologous tumour lesions.


2012 ◽  
Vol 7 (3) ◽  
pp. 274-293 ◽  
Author(s):  
Helge Gehrke ◽  
Anne Frühmesser ◽  
Joanna Pelka ◽  
Melanie Esselen ◽  
Lena L. Hecht ◽  
...  

2017 ◽  
Vol 18 (1) ◽  
pp. 1-9 ◽  
Author(s):  
Yunsheng Guo ◽  
Yan Pang ◽  
Xia Gao ◽  
Min Zhao ◽  
Xin Zhang ◽  
...  

2019 ◽  
Author(s):  
Rimsha Munir ◽  
Jan Lisec ◽  
Carsten Jaeger ◽  
Nousheen Zaidi

AbstractLipid droplets, the dynamic organelles that store triglycerides (TG) and cholesterol esters (CE), are highly accumulated in colon cancer cells. This work studies the TG and CE subspecies profile in colon carcinoma cells lines, SW480 derived from primary tumor, and SW620 derived from a metastasis of the same tumor. It was previously reported that the total TG and CE content is dramatically higher in SW620 cells; however, TG and CE subspecies profile has not been investigated in detail. The presented work confirms that total TG and CE content is significantly higher in SW620 cells. Moreover, the FA-composition of TGs is significantly altered in SW620 cells, with significant decrease in the abundance of saturated triglycerides. This resulted in significantly decreased TG saturation index in SW620 cells. The saturation index of CEs was also significantly decreased in SW620 cells. The saturation indices of some other major lipid classes were either similar or only moderately different between SW480 and SW620 cells. We also compared the expression of metabolic genes that may regulate these changes in the lipidomic profiles.


Sign in / Sign up

Export Citation Format

Share Document